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ABSTRACT
Studies of limb regeneration have implicated the nervous system
in promoting osteogenesis.

The neurotrophic hypothesis states that

neurons synthesize a substance, called a neurotrophic factor, which
is transported to distant tar.get organs or tissues.
Tn_ objective of this study was to investigate the direct

neural involvement in osteogenesis.

This study utilized in vitro

cell culture techniques, focusing on two known neurotrophic

substances, nerve growth factor (NGF) and vasoactive intestinal
peptide (V.IP).

The effect of these agents on the growth or’

phenotypio expression of the permanent, clonal osteoblastic cell

line, Rat Osteosarcoma (ROS 17/2.8) cells was assessed.
the ROS

17/2.8 cells was

Growth of

determined by the cell number (measured by

the coulter counter) and the osteoblastic differentiation was
determined by the specific biochemical assay of alkaline phosphatase

(AP, a specific

osteoblastic

marker).

The ROS

17/2.8 cells were

pre-incubated for 2 days in a culture medium consisting of modified

Ham’s F-12, I% kanamycin sulfate and 5% fetal bovine serum (FBS).
During the experimental period the cells were maintained with Ham’s

F-12, 2% FBS, I% kanamycin and the test agent.

The hypothesis was

that the addition of VIP and NGF alters the AP specific activity (Sp

Ac) or cell number of the ROS 17/2.8 cells.
NGF and VIP had the following direct effects on osteoblastic
growth and differentiation"

I

VIP increased the Ap Sp Ac and cell number, when measured
sixty hours following the initial addition of five doses of

0.165 ug/ml at 12

hour intervals.

This condition decreased

the protein content.

VIP had a similar effect when added

in a single dose of 0.825

2.

ug/ml.

VIP increased the AP Sp Ao and cell number, and decreased
the protein content when measured seventy hours following
the addition of a single dose (0.50

5.

ug/ml and 1.0 ug/ml).

NGF inhibited the AP Sp Ac and increased the cell number
and protein content when measured sixty hours following the
addition of a single dose

(0.025 ug/ml).

The phosphodiesterase inhibitor, isobutylmethylxanthine

(IBMX),

either alone o in combination with otheF agents

decreased AP Sp

5.

The effect of VIP in increasing AP Sp Ac was more

pronounced in the presence of IBMX and NGF.
These results are consistent with the hypothesis that the
osteobl-ast responds directly to the neurotrophic substances VIP and

NGF.

INTRODUCTION
The objective of this reseaFch was to investigate whether
vasoactive intestinal peptide

(VIP) and nerve growth factor (NGF)

act as direct regulators of skeletal cell physiology.

To est this

hypothesis, the effects of VIP and NGF on the differentiation or
proliferation of rat osteosarcoma (ROS)

1’7/2.8 permanent, clonal

osteoblastio cell line were examined.

Nerves regulate

the growth, maintenance and repair of target

organs or tissues, probably via specific chemical

substances

(Dubner

et al., 1978). This relationship, in which nerve cells and target
cells interact so as to influence the structure or function of
either member,

is called neurotrophism

(Drachman, 1974).

The neurotrophic hypothesis (Singer,

1978) states, neurons

synthesize a substance, called a neurotrophic factor which is

transported to distant target organs or tissues.

Much of the

evidence for neurotrophism comes from regeneration studies.

Regeneration of an amputated limb, has been reported in the

newt (Singer, 1952), rats (Becket, 1972; Libbin et al., 1979), mice

(Neufeld, 1980) and children (Douglas, 1972; Illingworth, 1974;
Rosenthal et al.,

1979).

Singer (1952) postulated that the role of nerves in
regeneration is mediated by a chemical trophic factor.

Both sensory

and motor fibers are able to maintain limb regeneration although a

larger number of motor fibers appear to be necessary (Singer, 1946,

1952).

The intensity of regeneration is determined by the number of

nerve fibers present (Guth, 1969).

When nerves grow into an

amputated aneurogenic stump, regeneration is accelerated

1959).

(Yntema,

When the nerves are resected after partial regeneration has

occured, further growth is prevented and the partial regenerate may

regress to the original amputation site (Singer and Craven,

1948).

Thus, the ner.vous system has been implicated in osteogenesis, bone
formation and resorption.

Since regeneration studies involve the

total system there is the complication of tissue interactions.

Therefore, a direct connection between limb regeneration and bone
growth is not proven in regeneration studies.

Utilizaton of the

cell culture technique would be helpful when investigating a direct

effect.
There have been conflicting reports of possible neural
involvement in skeletal physiology.

Some of the studies indicating

that the neural involvement is not important in skeletal physiology
include the findings of Corbin and Hinsey

(1939), that the skeleton

can be maintained even when completely denervated (1-3 sacral dorsal
and lumbar sympathectomy in cats).

Also, some investigators did not

find any changes in long bone growth in thoracolumbar

sympathectomized cats (Harris and McDonald,

1936; Cannon et al.,

1929), rats (Bacq, 1936), goats (Bisgard, 1938), dogs or lambs
(Harris and McDonald, 1936).

However, Harris and McDonald (1936)

stated that muscular activity was essential to normal growth and
that sympathectomy would not produce visible changes in leg length
in cases of extensive paralysis.

Ashton (1980) reported

osteogenesis occured in mil lipore filter chambers in the total

absence of neural celis.

However, the "in vivo" environment, seemed

essential for this process.

Denervation studies should be interpreted carefully since such

experiments result in muscular, circulatory, neuronal and disuse

effects.

During surgical denervation, there is the complicating

factor of muscle damage, which is important when inteFpreting the
Fesults.

Also, in Fegional migratory osteoporosis, which is

transient localized demineralization, the muscles overlying the

affected area are denervated.
neuFal involvement via NGF

Thus, this in vitro study of the

and/or VIP

is an alternate approach to

this question regarding skeletal physiology.

The first neurotrophic substance to be identified was NGF

(Bueker, 1948).

NGF has been pFoposed as a possible agent

regulating trophic interactions in the peripheral nervous system

(Varon and Bunge, 1978).

Greene and Shooter (1980) suggest a

possible extraneuronal role for NGF.

Specific binding sites for NGF

have been found in the brain, adrenal gland, heart, abdominal aorta,

liver, spleen, uterus, kidney, diaphragm and skeletal muscle

(Frazier et al., 1974).

A possible role for NGF in bone remodeling was reported by
Teitelbaum et al.

(1978).

The effects of NGF on maintaining cranial

bone and cartilage as differentiated neural crest cells were

discussed by Coulombre et al. (1974).
Weis and Weis

(1970) found an

increase in the length of

regenerating limbs and in the rate of digit formation in Ambystoma
following administration of NGF.
Saide et al.

(1975) observed that patients with Paget’s disease

(intense bone remodeling and rapid proliferation of fibroblasts)
have higher serum concentrations of NGF.

VIP is a single chain peptide of 28 amino acids, mol. wt.

VIP was first isolated from porcine small intestine (Said

33OO.
and

Mutt, 1970) and has

since been localized within neurons by

radioimmunological and immunohistochemical methods (Fuxe et al.,

VIP is synthesized as part of the po lyprotein, pre-proVIP.
Tsukada et al. (1985) have isolated and determined the structure of
the human vasoactive intestinal po lypeptide gene.

Marie et al.

(1985) found that the tyrosyl residue (Tyr-22) and the localized
hydrophobio features of VIP are critically involved in the function

of V IP.

In the periphery, post-ganglionic parasympathetic neurons

containing VIP innervate blood vessels and secretory epithelial

cells where

electrical

stimulation results in an increase in

VIP,

which causes vasodilation and secretion in salivary glands

(Fahrenkrug, 1979; Uddman et al., 1980).

Scott and Baum (1985)

reported that cAMP and calcium were involved in the exocrine protein
secretion induced by VIP in rat parotid cells.

VIP also

synergistically stimulated parotid secretion when combined with
substance P, another neurotransmitter and a sialogogue (Ekstrom and

Olgart,

1986).

VIP is a putative neurotransmitter in the system referred to as
the peptidergic nervous system (Sundler et al.,

called VIPergic system (Polak and Bloom,

1982).

1980) or the so
Under conditions of

electrical blockade, Brenneman and Eiden (1986) demonstrated the
neurotrophic action of VIP on neuronal survival.

VIP has a large

spectrum of important biologic activities including it’s effect on
blood flow, smooth muscle relaxation, exocrine secretion and

endocrine, neuroendocrine activity.

For certain agents (PTH, PGE) the irst step in the stimulation
of bone resorption is probably binding of the hormone to specific

cell surface receptors, followed by the activation of adenylate

cyolase and increases in cAMP.

Hohmann and coworkers (1983) found

that VIP causes a dose-dependent increase in bone resorption via a

cAMP-dependent, prostaglandin (PG) independent mechanism.

It has

been suggested that most agents that increase cAMP levels in bone do

so via the osteoblast, which then act to stimulate and/or recruit
the osteoclast, resulting in bone resorption (Rodan and Martin,

1981).

Hohmann and Tashjian (1984) found that human osteosarcoma

cells respond to VIP with an increased production of cAMP which is
mediated by speciio surface receptors for VIP.

McSheehy and

Chambers (1986) report that osteoblastic cells mediate osteoclastic
responsiveness to

PTH, which is also consistent with Rodan and

Martin’s (1981) hypothesis.

Some clinical findings of relevance are-

I.) The report of a

case of VlP-secreting ganglioneuroma with the predominant clinical
picture of growth failure with intermittent secretory diarrhea and

soiling.

The short stature with severe growth failure was a

dominant feature in the absence of weight loss, malabsorptin or ill

health (Granot et al.,

1983).

2.) Kaplan and coworkers (1980)

reported earlier on a VIP secreting tumor of childhood which
included in the clinical picture, failure to thrive, with the
child’s height and weight below the third percentile.

Laburthe et al. (1986) reported that AC-Tyrl hGRF (human growth

hormone-releasing factor with position I substituted .Ac-Tyrl analog)
is a competitive VIP antagonist in the rat.

N-terminal histidine

(position I, Hisl) is important for peptide interaction with VIP
receptors.

Chihara and coworkers

(1984) report the stimulation of

growth hormone by VIP in acomegaly.

Previous studies found that

VIP stimulates GH secFetion fom GH-seceting pituitary adenoma i__qn
vitro (Chihara et al.,

1982; Matsushita et al., 1981). Again, these

conflicting reports, on the possible involvement of the nervous

system indicate the complexity of the total system.

Therefore,

utilization of cell culturing may provide useful information

regarding a direct effect.
The rat osteosarcoma clonal cell lines (ROS) were selected on

the basis of parathyroid hormone-sensitive adenylate cyolase.
cells express the following osteoblastic characteristics:

These

elevated

AP, I ,29-(0H)2 vitamin D 3 receptors, bone -carboxyglutamic acid
protein synthesis stimulated by 1,25-(0H) 2 vitamin D 3, osteogenesis
in subcutaneous tumors and implanted Millipore filter chambers

(Majeska et al., 1980).

In R0S 17/2.8 cells, proliferation and

phenotypic expression (exemplified by cell number’ and AP activity)
is modulated by hormones known to affect bone

(e.g. PTH).

Even

though differentiation is coupled to growth aFrest, the arFest of

gFowth does not necessarily result in differentiation.

Therefore, the goal of this study is to provide insight into
possible direct effects of the nervous system on osteoblasts.

Specifically, the effect of VlP and NGF on growth and
differentiation was investigated.

ObOeqt. ive and Hypqthgsis
The obOeotive of this study is to investigate the neural
involvement in osteogenesis.

As discussed under the Introduction

section, neurotrophism has been investigated mostly via regeneration
studies of the limb.

These in vivo studies are difficult to

interpFet because of the muscular, circulatory, neuronal and disuse

effects.

This study utilized in vitro culture techniques;

focusing on two known neurotrophio substances, NGF and VIP.

The

effect of these agents on growth or phenotypic expression of the

permanent, clonal, osteoblastic cell line, Rat Osteosarcoma (ROS

17/2.8) were assessed by determining the cell number and by the
specific biochemical assay of alkaline phosphatase (AP).

Alkaline

phosphatase is a specific osteoblastic marker, used to determine
osteoblast differentiation.

In summary, the objective was to determine if VIP and NGF
effect the differentiation or pro liferation of ROS 1 7/2.8 ce I I s.
The hypothesis is that the addition of VIP and NGF alters the AP
specific activity or cell number of ROS

17/2.8 cells.

MATERIALS AND METHODS
Materials

Cell culture medium, serum and antibiotics were purchased from

GIBCO, Grand Island, NY.
Cambridge, MA.

Culture plastioware was from COSTAR,

Hepes, 2-amino-2-methyl-l-propanol, disodi.um p-

nitrophenylphosphate, p-nitrophenol, vasoactive intestinal peptide

(VIP),

Tris

(hydroxymethyl)-aminomethane and bovine serum albumin

(BSA) were from Sigma, St. Louis, MO.
and

Haas, Philadelphia, PA.

Triton X-tO0 was from Rohm

Isobutylmethylxanthine

Aldrich Chemical Co., Milwaukee, WI.

(IBMX)

was from

7S-Nerve Growth Factor was from

Collaborative Research, Inc., Lexington, MA.

Populati_on

to b__e Stdied

The permanent, clonal osteoblastic cell line, Rat Osteosarcoma

(ROS 17/2.8) cells was utilized to facilitate the study of
osteoblastic cells in culture.

Cell culture minimizes differences

between experiments due to heterogeneity and the loss of phenotypic
properties, which are present in organ culture and primary cell
cultures.

Cell Culture and Maintenance
The maintenance medium consisted of modified Ham’s F-12

(Majeska and Rodan, 1982a) containing I% kanamycin sulfate and
supplemented with either 10% or
Cultures were kept at

37C

5% fetal

bovine serum

in a humidified

atmosphere, and were subcultured weekly.

I0

(FBS).

95% air/5 CO 2

Ce l____!l

.C 0un. t ing
FoF expeFiments, cell suspensions were prepared at the
ml portions were

appropriate density for each expeFiment, and

plated in 24 multiwell plates.

The following proceduFes were performed, to plate out 20,000

cells/well [in a 16 mm diameter well (P-16)
of 2 cm 2 and a medium volume of I ml].

which has a culture area

First, the medium was

aspirated from a P-tO0 (100 mm diameter culture dish) of confluent

ROS ce i i s.

Next, 2.0 ml of 0.01% trypsin was added for 5 minutes,
Next, 0.5 ml of 0.01% trypsin was

then the trypsin was removed.

added to the culture plates which were placed in the incubator at

57C

for 8-I0 minutes.

This was followed by re suspension of the

cells in 10 ml of medium

(5%FBS, I% kanamycin). Then the cell

suspension was pipetted into a 16 ml tube; the cells were thoroughly
mixed by pipe tting up and down.

With the same pipette, 0.5 ml was

removed aseptically and added to 9.5 ml saline (0.9 NaC1) in a

cuvette.

Each sample was counted three times.

The number of cells per milliliter in the test tube was
determined by the average count, which is multiplied by .40 because

of the following calculation"

Average count (# of cells) x 10 ml total volume/0.5 ml sample size x

/0.5 -ml coulter counting
Average count(number of cells) x 0

number oZ

volume

oells/ml

The seeding density of 20,000 cells/well, which is equivalent to

10,000 oells/cm 2 was prepared utilizing the determined number of

cells/ml.

Since each well contains a medium volume of I ml, the

appropriate number of cells were removed from the test tube and

placed in a sterile bottle with the correct

amoun

of medium.

For example, if the average cell count was 19,754 cells x 40

In experiment #I, 100 welis required 20,000

790,147 cel is/ml.

cells/well necessitates 2,000,000 cells/lO0 wells.

Since there were

790,147 cel ls/ml a 2.53 ml aliquot was removed and placed in 97.47
ml medium (%5 FBS, I% kanamycin).
added to each of the 100 wells.

Then I ml of this mixture was
The preincubation period was 2

days.

At the end of each experiment, the following procedure was used
The medium was fir st

count the number of celis per 16mm well:

aspirated from each well and the cells were rinsed once with CMFH.

Then 0.5 ml of 0.01% trypsin was added to each well and the plate

was incubated at

37C

Zor 8-10 minutes.

Next, 0.5 ml saline (0.9%

NaCL) was added to each well; the cells were resuspended and
pipetted into pre-loaded cuvettes containing 9.0 ml saline.

sample was counted three times.

Each

This average count was for the 0.5

ml aliquots of the 10 ml in each cuvette.

Therefore, each average

value of the cell counts was multiplied by a factor of 20, in order

to obtain the actual number of cells/well.

.A!kal_ne Phospha_t_ase Assa_____
First, the medium was aspirated from the wells; then each well

was rinsed once with CMFH, followed by the addition oZ 0.5 ml oZ the
sample buZZer (lOmM Tris-HCl, pH 7.5, 0.5 mM

I00) to each well.

MgCI2, 0.1%

Next, the wells were scraped

triton X-

with a plastic

scraper and the sample were pipetted into plastic test tubes and
either kept on ice or frozen until assayed.

Ten microliter aliquots of the sample were placed in duplicate
12

test tubes and kept on ice.

At time

O, 0.180 ml of the alkaline

phosphatase assay mixture containing 0.I M 2-amino-2-methyl-1propanol, 2mM

MgC12,

2 mM Na 2 p-nitrophenylphosphate

added, followed by vortexing and incubation in a

(Na2PNPP)

37C

was

water bath.

The reactions were stopped with 0.8 ml of 1.0 N NaOH and the
absorbance was read at 410 nm.

When using ROS

17/2.8

the reaction

is linear for about 20 min with up to 3 ug of protein.

rotein_ eteminatio_n_ b_z Coomassi_e Blu___e G_ (_Spector,1978)Duplicate assay tubes were prepared containing 10 ul aliquots

of each sample.

To each assay tube 100 ul o.f

H20

protein standard curve was prepared usi.ng the 500
solution of BSA as foliows:

(100 ul of BSA + 900 ul of

A

ug/ml stock

The BSA stock solution was diluted 1:10

H20).

A series of tubes (duplicates)

were pepared containing O, I, 2, 5,
equivalent to O, 20, 40,

was added.

or 5 ug of BSA.

This is

60, 80 or 100 ul of the diluted stock BS.A.

Each standard is brought up to a volume of 100 ul with

H20.

Then,

to each standard tube 10 ul of sample buffer (10 mM Tris-HCl pH 7.5,

0.5 mM MgCI 2, 0.1% Triton X-tO0)was added.

To all test tubes

(samples and standards) 900 ul of the Coomassie Blue G reagenc was
added.

The test tubes were allowed to stand at room temperature for

5 min.

Then the absorbance was read in the spectrophotometer at 595

nm.

Protein concentrations were determined using standard curves

obtained by linear regression analysis.

Al_kali_n e Phosphatase Detrminatio n
The specific activity (Sp Ac) of alkaline phosphatase (AP) was

Spec_ifi c

Ac.t. ivit._.y__ of

determined using the following equation:

Sp Ac (umole/min/mg protein)

O.0574/Tmin/Protein

rag; where T

(Xab41 0

Blankab410)

x

"5 minutes in experiment

and # 5

and T

4 minutes in experiment #2, X

Blank

absorbanoe at 410 nm of 180 ul Buffer + 800 ul NaOH, 0.0574

mean absorbance st 410 nm,

is derived from the molar extinction coefficient of p-nitophenol,

Values for Sp Ac were calculated for each

the reaction product.

well, the means and standard deviations were determined for each

group using these values.

p.r=_e_=par_ation of Substances:
Vasoactive intestinal peptide

(0.25 mg VIP) was dissolved in

1.0 ml of 0.I HAC, 0.1g BSA, pH 4.0.

ug VIP/ml HAC-BSA).

This was the stock VIP

(250

The control (vehicle) for VIP was HAC-BSA.

NeFve growth factor (100 ug NGF) was dissolved in 1.0 ml medium

(2 FBS, I% kanamyoin).
medium).

This was the stock NGF

(I00 ug NGF/ml

NO GLASS WAS USEDWITH NGF (plastic pipettes were used).

The control (carrier-vehicle) foF NGF was the culture medium (2

FBS, I% kanamyoin).
The stock 20 mM IBMX was prepared by dissolving 4.4 mg IBMX in

1.0 ml of 0.2 N NaOH.

The control (carrier-vehicle) for IBMX was

0.2 N NaOH.
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Treatment of 17/2.8 Cultures with Vasoactive Inte.si_na_! P.9tide,_
Nerve Growt-- Factor a---d IB-----X-----Experiment # Design:

ROS 17/2.8 cells previously maintained in I0% FBS were seeded
into one

4 well (16 mm) and four 24 well (16 ram) plates at a density

of 0,000

cells/om 2 (20,000 cells/well)

medium.

After 2 days, two-wells were assayed for cell number, and

in

two for alkaline phosphatase and protein.
fed with medium containing

5 FBS, I

kanamyoin

The remaining wells were

2% FBS and test agents as shown below.

In experiment #1a, one dose of 0.825 ug VlP/ml was added to two of
the

24 well plates.

In experiment #1b, 5 doses of 0.165 ug VIP/ml,

at 12 hour intervals was added to the two remaining 24 well plates.
Sixty hours following the initial addition of the agents, alkaline

phosphatase., protein content and cell number were determined.
Figure I.

Experiment #1 Design

C

VI+N

C
V1
0 0 0 0 0 0
2
1
0 0
0
0
0
0

N
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I dose at t
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’00lo 0 0 0
6

5

each well.

000000
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I

COUNT
000000

0 0 0 0 0 0

8

7
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0.025 ug NGF/ml in

N

each well.

000000

0 0 0 0 0 0

I

N+I

VI+I VI+I+N
V2+I
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10
9

Control carriervehicles only.

__N

V2

<---- AP-----}

N+I_

5 doses at 12 hour

V2
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dose resulting in

000000

14

15

0.165 ug VIP/ml

0 0 0 0 0 0

each we I i.

COUNT
0 0 0 0 0 0

o 0_._._.2o o o o!’.
V2+I+N V2+N

AP

q

15
0

0,0lJ 0 0
C

I
15

t

0

in

Experiment #2 Design

One 4 well (6mm) and two 24 well (6mm) plates were seeded at
The cells were grown for 2 days in 2% FBS,

30,000 cel is/16mm well.

I% kanamycin medium, then fed

with

0.2% FBS, I kanamycin medium

containing test agents shown below.

Ninety-six hours following the

addition of the agent, alkaline phosphatase, protein content and
cell counts weFe determined.

Figure 2.

Experiment #2 Design

C

Control
carriervehicle

C

C

V3

o 0o

---AP

’0 0

COUNT

i

2
0 0 0 0 0 0

ooo

0-0o

0 0 0 0 0 0

N

AP-----+

NI+V3

V4

0

0 0-0

0 0 0 0 0 0
0 0 0 0 0 0
N2 N2+V4

t

V5

1.0 ug VlP/ml

V4

0.5 ug VlP/ml

N1

0.25 ug NGF/ml

N2

0.1 ug NGF/ml

0

Experiment #5 Design

Two 24 well (16ram) plates were seeded at a density of 20,000

cells/16mm well.

The cells were grown for 2 days in

kanamycin medium, then fed with

5% FBS, 1%

2% FBS, 1% kanamycin medium

containing-the concentrations of VIP illustrated in Figure 3.

Cell

counts, AP and protein measurements were performed 70 hours after
the addition of the test agents.

16

Figure 5.

Experiment #5 Design

Count
C

Alkaline Phosphatase:

C

c

Control
carriervehicle

Vl
0 0 00 0 0
2
1
0 0 0 0 0 0

ooo

2
0 0 0 0 0 0

Vl

0.5 ug VlP/ml

0 0 0 0 0 0

0 0 0 0 0 0

V2

1.0 ug VlP/ml

0 0 0 0 0 0

0 0 0 0 0 0
v2
v5

V3

1.5 ug VlP/ml

0

o o
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RESULTS

In this study, both of the neural factors, NGF and VIP had
direct effects on the ROS cells.

In experiment #1a, the addition of

one dose of 0.825 ug VIP/ml produced small increases in AP specific
activity and cell number and a decrease in the protein content.

In

comparison to untreated controls, by the T-test, these were small.

Similarly, NGF increased the cell number and protein content; and
inhibited AP activity.

The effect of IBMX was marked.

When IBMX was compared to the

untreated control, using the T-test, there was a decrease in AP
specific activity and cell number, and a significant increase in
protein content.

In Experiment #1(a+b), all of the values of AP Sp

Ac which were significantly decreased had IBMX added.

IBMX is a

phosphodiesterase inhibitor, which inhibits the destruction of cAMP.

Binding of a hormone to a membrane receptor induces intracellular

cAMP.

Cyclic AMP activates protein kinases which phosphorylate

intracellular proteins.

Cyclic AMP is synthesized from ATP by the

plasma membrane bound enzyme, adenylate oyolase, and is rapidly

destroyed by phosphodiesterase.
While few of -these effects were significant when analyzed by

the T-test, the 5-way ANOVA showed a significant effect.

The

Three-Way Analysis Of Variance (5-Way ANOVA) was performed on the
values in Table

with the results shown in Table 2.

When VIP was

added a significant difference was found in AP Sp Ac and protein
When NGF was added, a significant difference was found in

content.

AP Sp .Ac.
in AP Sp

When IBMX was added, a significant difference was found

Ao, cell number and protein content.
18

When VIP + IBMX was

added, an interaction was found to affect the protein content.

When

NGF + IBMX were added, an interaction was found to affect the AP Sp

Ac and protein content.
Then, in experiment #1b, when five doses of 0.165 ug VlP/ml was
added at 12 hour intervals, there was an increase in AP Sp Ac and
cell number and a decrease in protein content.

Similarly, NGF

stimulated AP activity and cell number and inhibited .protein

content.
The 3-Way ANOVA was performed on the values from Table 3, with
the results shown in. Table 4.

When VIP was added in five doses, at

12 hour intervals, a significant effect was found on AP Sp Ac, cell
number and protein content.

affect on cell number.
and cell number.

The addition of NGF had a significant

The addition of IBMX affected the AP Sp Ac

An interaction was found with VIP + NGF on the AP

Sp Ac, cell number and protein content.

In experiment #2, within one plate, using the T-test to compare

0.25 ug NGF/ml to the untreated control, there was a significant
increase in cell number, and on the other plate, the addition of 0.1

ug NGF/ml produced a significant decrease in AP Sp Ac.

However, the

variation between controls on the two plates was so large that is

was not possible to deduce effects of VIP and NGF.
Experiment

#3 was designed to replicate the experimental

conditions in experiment #1a, with respect to plating density, and

the length of the treatment period.

In this experiment, with a

larger sample size, the effects were small and not statistically
significant, although the direction was the same as experiment #I.

Also, at the highest concentration (1.5 ug VlP/ml) tested, a
reversal of this effect was observed.
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Table 1. Experiment #1a, Number of CelIs/Well, Protein Content and
Alkaline Phosphatase Specific Activity Following
Addition of Agents to ROS 17/2.8 Cells

[VIP]
ug/ml

[NGF]
ug/ml

[IBMX]
mM

0

0

0

6.464

825

0

0

825

0

.82

AP Sp Ac
umol/min/mg

Cell Number/Well
x I0
mg protein

.1264

.0770 + .0104

.613

6. 779 + 0.965

.0690

.727 + .1228

.2

4. 877 + 0.922

.0758 + .0023

.323 + .0214"

.025

.2

6.076

+ 0.730

.0735 + .0221

.362

.825

.025

0

6.264

+

1.476

.0813 + .0023

.552 + .0643

0

.025

0

7.346

+

0.656

.0990 + .0035* .462 + .0523

0

.025

.2

6. 398 + 0.361

.1093 + .0014" .236 + .0182"

0

0

.2

5. 728 + 0.266

.1195 + .0095" .228 + .0047"

/

1.235

+ .0017

+

+ .0839*

All values are the mean +SD.
The test agents were added for 60 hours in 2% serum.
*Significant difference at P<.05 when compared to untreated contro I s.

Table 2. Experiment #1a, Analysis Of Variance For Values From
Table 1

Factor

F Value For Effect On
Cel I Number
AP Sp Ac

Protein Content

46. 450**

VIP

11.849"*

1. 501

NGF

5.097*

2.004

95.060**

5. 685*

VIPxNGF

0.003

0.303

0.0116

VIPx IBMX

O. 018

0. 067

1 2. 058**

NGFxIBMX

9.115"*

0.899

9.512"*

O. 189

1 490

1.258

IBMX

VIPxNGFxIBMX

2.151
11 61 3**

Significant effect of factor or factors (axb) on AP Sp Ac, Cell
Number and/or Protein Content at** P< .01 *P <.05

2O
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Table 3. Experiment #1b, Number of Celis/Well, Protein Content and
Alkaline Phosphatase Specific Activity Following Addition
of Agents to ROS 17/2.8 Cells

[ NGF]
ug/ml

[ IBMX ]
mM

.165x5

0

0

165x5

0

[VIP]
ug/ml

Ce I i
xl

Oumbe r/We

AP Sp Ac
umol/min/mg

ii

mg Protein

7.311 + 0.180"

.0662 + .0104" .722 + .1422"

.2

6.424

.0703 + .0161" .459 + .1474

165x5 .025

.2

5. 384 + 1.484

.09’77 + .0271

165x5 .025

0

8.645

+ 1.371"

.0795 + .0188" .617 + .1154"

0

.025

0

6.947

+

1.077"

.0852 + .0037* .541 + .0885*

0

.025

.2

5.659

+

0.677

.0957 + .0054* .299 + .0243*

0

0

.2

3.111 + 0’931

.1140 + .0162

.243 + .0340*

0

0

0

4.523 + 1.345

.1075 + .0028

397 + .0588

+

0.299*

.283 + .0890"

All values are the mean +SD
above initial test agents were added for 60 hours in 2% serum.
Significant difference at P<.05 when compared to untreated controls.

Table 4. Experiment #1b, Analysis of Variance For Values From
Table 3

Factor
VIP

F Value For Effect On
Cell Number
AP Sp Ac

12.814"*

22. 361"*

Protein Content

11.821"*

10.956"*

0,000

35. 061 **

18..527**

2,326

VlPxNGF

8.21 5**

8. 646**

9. 947**

VIPxlBMX

I 438

O. 829

0.0428

NGFx IBMX

O. 91 6

2 000

O. 487

VIPxNGFx IBMX

0.011

2.464

0.150

NGF

IBMX

0.235

Significant effect of factor or factors (axb) on AP Sp Ac, Cell
Number and/or Protein Content at **PK .01 *P < .05
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Table

.

Experiment #2, Number of Cells/Well, Protein Content and
Alkaline Phosphatase Specific Activity Following
Addition of VIP and NGF to ROS 17/2.8 Cells

[VIP]
ug/ml

[NGF]
ug/ml

0

Cell Nmber/Well
x10

mg Protein

AP Sp Ac
umol/m_.n/mg

0

10.110 + 2.417

.037 + .0113

2.298 + .4152

1.0

0

14.226

.043 + .0047

2.144 + .3629

0

.25

14. 171 + 1.836"

.043 + .0078

2. 163 + .4]583

1.0

.25

14.351 + 2.642

.044 + .0120

2.095 + .5401

0

0

14.455 + 1.874

.043 + .0168

2.863 +1.4490

5

0

16.039

+ 1.211

.047 + .0184

2.300 + .8287

0

.1

13.905 + 2.789

.053 + .0100

1.716

5

.1

16.166 + 3.283

.053 + .0245

2.479 +1.1844

+ 2.826

+

.3012"

All values are the mean +SD.
The above test agents
added for 96 hours in 0.2% serum medium.
*Significant difference at P<.05 when compared to the untreated
controls.

were

Table 6. Experiment #3, Number of Cells/Well, Protein Content and
Alkaline Phosphatase Specific Activity Following Addition
o VIP to ROS 17/2.8 Ceils

[VIP]
ug/ml

Cell

Number/Well

umol AP/min

x 10"

AP Sp Ac
umol/min/mg

mg Protein

0

4.100 + 0.945

.064

+

.0099

.057 + .0050

1.172 + .1294

5

4.544 + 0.558

.068

+ .0081

.053 + .0089

1.386

1.0

5.021 + 0.817

.063

+

.048 + .0108"

1.445 + .4762

1.5

4.649

.057 + .0115

.052 + .0077

1.125 + .1570

+

1.056

.0069

All values are the mean +SD.
VIP was added for 70 hours in 2% serum medium.
*Significant difference at P(.05 when compared
controls.
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untreated

+

.2964

Experiment #3, AP Specific Activity, Cell Number and Protein Content.
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DISCUSSION
This study shows that VlP and NGF has a direct effect on

osteoblasts in culture.

Even though differentiation is coupled to

growth arrest, the arrest of growth does not necessarily result in

diffeFentiation.

Therefore, when studying the effect of NGF and/or

VIP on ROS 7/2.8 cells both growth (cell number) and
differentiation (AP Sp Ac) were investigated.

However, under the

conditions of experiment #I, the effect was small, when compared to

the untreated control using the T-test.

The effect of VIP was more pronounced in the presence of IBMX
and NGF, which antagonize it.

This is apparent when the 3-way ANOVA

was calculated; not only was there an effect of the VIP, NGF and

IBMX alone, but also an interaction (axb) on the AP Sp Ac, cell
number and protein content.
Experiment #I indicates that the addition of the

phosphodiesterase inhibitor, IBMX, either alone or in combination
with other agents tends to cause a decrease in specific activity of

alkaline phosphatase.

These results following the addition of IBMX

agree with previous findings in the laboratory (Maeska and Rodan,

1982b).
Experiment #2 was designed to increase the experimental time
period from the 60 hours in experiment #I to

96

hours in experiment

#2, to investigate further the effect of the agent on cell growth.
Another important alteration in experiment #2 design was a decrease
in the concentration of serum to

0.2 FBS to reduce its effects when

examining the influence of VIP and NGF on the growth and maturation
of ROS

17/2.8 cells.

This is important because the presence of
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serum adds a complicating factor because serum binds and contains
Of course, a seum fee medium

many gowth and maturation factors.

would eliminate the complicating factor of seum, but also adds a
different factor, which is the difficulty for cell gFowth and
maintenance.

Other relevant changes in experiment #2, aFe that VIP was given
in one dose, the NGF conoentFation was increased and there was a

control on every plate.

However, experiment #2 was inconclusive;

the difference in control values may be due to the relatively small

sample size and large SD.

Therefore, Experiment #3 was designed to increase the sample
size and to investigate vaFious concentrations of

VIP.

The

experimental design of experiment #5 was similar to Experiment #
with respect to serum concentration and plating density.

The

results of experiment #5 suppoFt the Fesults of experiment #I:
addition of VIP in the same concentration Fange

increased AP Sp

(0.5-.0 ug VIP/ml),

Ao, oel.l number, and decFeased the protein content.

At the highest concentration tested (1.5 ug VIP/ml) the effect was
reduced.
The biological effect was unexpected.

The effects in the

presence of IBMX appear to be the opposite of what one might expect.
Previous studies showed that PTH and isoproterenol ,increase cAMP and
decrease AP in ROS

17/2 cells.

Since VIP increased cAMP in bone and

human osteosarcoma cells, one might expect an inhibition of AP in

R0S

17/2.8 cells.

Since VIP antagonized the IBMX inhibitory effect

on AP, its action may not have a simple relationship to changes in

cAMP levels.

In this studyVlP increased the AP Sp Ac.

Also,

Hohmann and Tashjian (1984) reported that VIP increased-cAMP in the
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human osteosarooma cells.

Hohmann and

TashOian (198) have

routinely used IBMX and found that IBMX stimulated cAMP.
intestinal peptide and IBMX enhanced the production of

Vasoactive

cAMP; and

IBMX potentiated the resoptive response to low concentrations of
VIP.
In this study, the effects of VIP and NGF were found to be
small, suggesting that the ROS cells are low in receptors for these

agents.

This may be a property specific to the ROS

17/2.8 clone.

Grigoriadis et al. (1985) reported on the subclone heterogeneity of
the ROS cells.

Analysis of mixed osteoblastic cell populations or

other cloned osteoblastio lines may yield greater responses.

In

that case, selection of cells on the basis of response and/or number

of receptors for VIP and/or NGF, may be useful to study the direct

effect of V IP and NGF on osteoblasts.

Two postulated general roles of the nervous system in
mechanically induced tissue remodeling are: I) The stimulated nerves

could dilate capillaries at compression sites, leading to rapid
release of inflammatory cells that actively participate in the
invasion of the hyalinized zones.

2) A direct effect of a

neurotrophic substance, such as VIP which is secreted from the

nerve,

causes

a response in the osteoblast.

The results reported in

this study are consistent with this hypothesis.

Also, Hohmann and

Tash$ian’s (1984) findings of functional receptors for VIP on human

osteosarcoma cells (SaOs-2), and the finding that VIP stimulates
bone resorption (Hohmann et al.,

1983);

which further

supports the

proposed interaction of osteoblasts and osteoclasts (Rodan and

Martin,

1981).
28

Summary and Conclusions
This investigation was undeFtaken to assess a direct neural
involvement in osteogenesis.

Two neurotrophio factors, NGF and VIP

17/2.8 cells.

had the following effects on the ROS

I.

VIP increased the AP Sp Ac and cell number, when measured
sixty hours following the initial addition of five doses of

0.165 ug/ml at 12

hour intervals.

the protein content.

VIP had a similar effect when added

in a single dose of 0.825

2.

This condition decreased

ug/ml.

VIP increased the AP Sp Ac and cell number, and decreased
the protein content when measured seventy hours following
the addition of a single dose

5.

(0.50 ug/ml and 1.0 ug/ml).

NGF inhibited the AP Sp Ao and increased the cell number
and protein content when measured sixty hours following the

addition of a single dose

4.

(O.025ug/ml).

IBMX, either alone or in combination with other agents
decreased AP Sp Ac.

5.

The effect of VIP in increasing AP Sp Ao was

moe

pFonounoed in the pFesence of IBMX and NGF.
These results aFe consistent with the hypothesis that the

osteoblast responds directly to the neurotrophic substances VIP and

NGF.
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